

The principles of the Economic Evaluation and Public Health Committee (CEESP) doctrine at the French National Authority for Health (HAS)

Yasmine Fahfouhi¹, Marine Sion¹, Salah Ghabri¹

¹. French National Authority for Health (HAS), Saint-Denis La Plaine, France


OBJECTIVES

- HAS critically appraises economic evaluations submitted by pharmaceutical companies for all innovative medicines and medical devices with a potential impact on health insurance spending (~25 products annually).
- Our objective was to **describe the CEESP doctrine²** used in the appraisals of economic analysis of health products.

². Doctrine of the Commission for Economic and Public Health Evaluation, HAS, 2022. www.has-sante.fr/jcms/p_3289120/fr/doctrine-de-la-commission-d-evaluation-economique-et-de-sante-publique-ceesp

RESULTS

- This work facilitated the sequential definition of 3 main components of the CEESP doctrine and its specific aspects (Figure 2):



DISCUSSION

- The CEESP doctrine outlines the key principles to carry out the appraisals of economic evaluation of innovative health products.
- The deliberative process based on the CEESP doctrine may be improved by including a pragmatic graduation of the uncertainty level.


CONCLUSION

- The CEESP doctrine is an evolutive tool that helps to ensure:
 - consistency and transparency of the economic appraisal process and their conclusion;
 - the equal treatment of manufacturers' submissions regarding the current knowledge on the intervention and the disease being studied.

Acknowledgements: we would like to thank the members of the CEESP involved in the doctrine elaboration, Dominic THORRINGTON and the Scientific Project Managers who participated in the working group.

METHODS

- The CEESP doctrine was elaborated in three steps (Figure 1):



- The process allowing the CEESP conclusions on the results of economic evaluation of innovative health products is described in Figure 3:

